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A 60-year old patient with a clinical history of peripheral
vascular disease and joint pains presented with a slowly
progressive painful mass in the left hip region. Twenty-
five years previously, he had been diagnosed with calcifica-
tions in the left hip region, and several operations had been
performed. His family history was negative for tumoral
calcinosis. Laboratory investigation showed a normal serum
calcium level, elevated serum phosphate level, normal renal
function, normal parathyroid hormone (PTH) level, and a
slightly elevated level of 1,25-dihydroxy-vitamin D. Urinary
calcium excretion was low, phosphate excretion was low.
Tubular maximum phosphate was elevated [2.33 nmol/l
(normal 0.8–1.3nmol/l)].
Pelvic X-ray and magnetic resonance imaging (MRI)
showed a giant calcified mass (Figures 1 and 2). Surgical
biopsy showed a bloody, milky, fluid, with calcifications.
Histological evaluation was characteristic for tumoral
calcinosis.
Tumoral calcinosis is a rare autosomal recessive
disorder, characterized by hyperphosphataemia due to
an increase in proximal tubular phosphate transport. The
underlying defect might be a mutation in the GALNT3
gene, but mutations in the fibroblast growth factor (FGF)
23 gene have also been implicated. The inactivation of
FGF23 and GALNT3 mutations both result in lack of
FGF23 and result in hyperphosphatic tumoral calcinosis
with enhanced renal phosphate reabsorption. Serum
Fig. 1 X-Ray of the left hip region showing a large calcified mass
around the left femur.
Fig. 2 MRI of the pelvis showing extensive intramuscular calcifica-
tions without affection of the bones.
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normal range. The tendency of phosphate to complex
with calcium and cause hypocalcaemia appears to be
counterbalanced by increased production of calcitriol
and, perhaps, hyperphosphataemia-induced stimulation
of calcium reabsorption in the distal nephron. The
combination of hyperphosphataemia and normocalcaemia
results in a high calcium phosphate product and calcium
phosphate deposition in the skin and subcutaneous
tissues. Younger male patients and black people are
more frequently affected by this disease. Calcinosis is
often associated with diseases such as chronic renal
failure, primary hyperparathyroidism, hypervitaminosis D,
milk–alkali syndrome and massive osteolysis.
Complete surgical excision has been recommended, but
recurrences are common. Phosphate depletion has proved to
have variable success. Therapy for tumoral calcinosis
consists of lowering the phosphate level with dietary
restriction, antacids that impair phosphate absorption and/
or phosphate binders. If this is ineffective, increasing
urinary phosphate excretion by the chronic administration
of acetazolamide might be beneficial. If patients are
informed of the familial risks, early stages of the disease
might be detected and treated.
In our patient, mutation analysis was not performed. He
was treated by protein restriction and with phosphate
binders and aluminium hydroxide, which resulted in a
reduction of the tumoral mass of 8 cm in 2 years.
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